Mother-infant pairs were randomized after delivery to immediately begin receiving 28 weeks of either triple maternal antiretrovirals ( zidovudine , lamivudine , and either nevirapine , nelfinavir , or lopinavir-ritonavir ) or daily infant nevirapine as part of the Breastfeeding , Antiretrovirals , and Nutrition ( BAN ) study .